uniQure N.V. (QURE)
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
- Symbol
- QURE
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $2.85B
- 52 week range
- 8.73 - 71.5
Valuation
- Share price
- $42.76 (close of 2026-09-23)
- P/E (TTM)
- -12.97x
- Price to book
- 19.11x
- Price to free cash flow
- -16.54x
- Enterprise value
- $2.78B
- Book value per share
- $2.37
Price performance
| Period | Change |
|---|
| 1 day | -3.50% |
| 5 days | -0.79% |
| 1 month | -11.60% |
| 3 months | -12.81% |
| 6 months | +168.59% |
| Year to date | +78.69% |
| 1 year | +213.03% |
| 3 years | +503.10% |
| 5 years | +11.88% |
| 10 years | +451.74% |
| All time | +192.68% |
Profitability and growth
- Return on equity
- -100.04%
- Return on invested capital
- -101.81%
- Return on assets
- -24.12%
- Return on capital employed
- -24.32%
- Gross margin
- 89.53%
- Net margin
- -1236.00%
- EBITDA margin
- -1059.70%
- Revenue growth
- -40.64%
- Net income growth
- 16.94%
- Free cash flow growth
- 4.13%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -6.05%
- Current ratio
- 10.40x
- Net debt to EBITDA
- 0.59x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $16.10M
- Cost of revenue
- $1.69M
- Gross profit
- $14.41M
- EBITDA
- $-170.59M
- Net income
- $-198.97M
- Earnings per share
- $-3.46
- Research and development
- $140.67M
- Shares outstanding
- 57.50M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|
| 2025-12-31 | $16.10M | $14.41M | $-198.97M | $-3.46 |
| 2024-12-31 | $27.12M | $25.85M | $-239.56M | $-4.92 |
| 2023-12-31 | $15.84M | $15.78M | $-308.48M | $-6.47 |
| 2022-12-31 | $106.48M | $105.23M | $-126.79M | $-2.71 |
| 2021-12-31 | $524.00M | $499.03M | $329.59M | $7.17 |
| 2020-12-31 | $37.51M | $34.62M | $-125.02M | $-2.81 |
| 2019-12-31 | $7.28M | $5.63M | $-124.20M | $-3.11 |
| 2018-12-31 | $11.28M | $10.08M | $-83.30M | $-2340.00 |
| 2017-12-31 | $13.11M | $12.29M | $-79.26M | $-2940.00 |
| 2016-12-31 | $25.10M | $23.75M | $-73.37M | $-2.93 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|
| 2025-12-31 | 89.53% | -1236.00% | -100.04% | -101.81% |
| 2024-12-31 | 95.33% | -883.35% | 3547.93% | - |
| 2023-12-31 | 99.59% | -1947.09% | -148.54% | -270.12% |
| 2022-12-31 | 98.82% | -119.07% | -26.64% | -36.25% |
| 2021-12-31 | 95.23% | 62.90% | 55.32% | 175.41% |
| 2020-12-31 | 92.27% | -333.27% | -51.26% | -154.58% |
| 2019-12-31 | 77.28% | -1705.82% | -38.45% | -661.06% |
| 2018-12-31 | 89.35% | -738.25% | -46.38% | - |
| 2017-12-31 | 93.77% | -604.72% | -88.70% | - |
| 2016-12-31 | 94.63% | -292.35% | -115.31% | - |
Cash and debt by year
| Period end | Cash | Debt |
|---|
| 2025-12-31 | $80.24M | $49.70M |
| 2024-12-31 | $158.93M | $51.32M |
| 2023-12-31 | $241.36M | $101.75M |
| 2022-12-31 | $228.01M | $102.79M |
| 2021-12-31 | $556.26M | $100.96M |
| 2020-12-31 | $244.93M | $35.62M |
| 2019-12-31 | $377.79M | $36.06M |
| 2018-12-31 | $234.90M | $35.47M |
| 2017-12-31 | $159.37M | $19.74M |
| 2016-12-31 | $132.50M | $19.63M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-178.40M | $17.68M |
| 2024-12-31 | $-186.10M | $22.26M |
| 2023-12-31 | $-153.08M | $35.09M |
| 2022-12-31 | $-162.75M | $34.20M |
| 2021-12-31 | $270.52M | $25.64M |
| 2020-12-31 | $-142.10M | $21.83M |
| 2019-12-31 | $-104.33M | $17.53M |
| 2018-12-31 | $-78.42M | $10.71M |
| 2017-12-31 | $-68.73M | $10.28M |
| 2016-12-31 | $-87.48M | $6.21M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-09
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-07-29 | Jun/2026 | - |
| 2026-05-05 | - | - |
| 2026-03-02 | - | - |
| 2025-11-10 | - | - |
| 2025-07-29 | - | - |
| 2025-05-09 | - | - |
| 2025-02-27 | - | - |
| 2024-11-05 | - | - |
Filings and sources
- Company website
- uniqure.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades